Answers are grounded in this paper and cite their sources.
The unique features of the human immunodeficiency virus (HIV) envelope protein have thwarted efforts to identify a protective vaccine. However, a vaccine that does not prevent infection but reduces HIV levels and preserves memory CD4+ T cells could benefit both the recipient and the community at risk. Several vaccines that induce T-cell responses are now in early clinical trials. This review summarizes the science and strategies in the search for an effective vaccine to control HIV infection.
No takes yet. Share an insight, caveat, or question.
Johnston et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: